This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.

Transforming Cancer Care with Cutting-Edge CAR T Cell Therapies

At VectorGene, we provide a turnkey solution for hospitals looking to establish CAR T-cell therapy labs. From training your staff, sourcing the equipment, setting up the lab, and developing the infusion center — we handle everything.

Get In Touch to Know More

Key Features

State-of-the-art CAR T Cell Vectors

Our CAR T cell vectors are precision-engineered using the latest advancements in biotechnology to ensure unparalleled efficacy and safety in cancer treatments.

Seamless Technology Transfer

We specialize in seamless CAR T cell therapy technology transfer, ensuring efficient, reliable, and scalable solutions for advanced cell-based treatments.

Comprehensive Training Program

We provide tailored training programs for clinicians and technicians, focusing on mastering CAR T cell therapy protocols, from preparation to patient care and infusion management.

Our CAR T Cell Therapy Vectors

We offer a comprehensive portfolio of high-quality CAR T cell vectors targeting key antigens in hematological malignancies and solid tumors.

CD19 Vector

CD19 Vectors

Demonstrates proven efficacy in B-cell malignancies, supported by extensive research and clinical application, contributing to improved treatment outcomes for patients.

Learn More →
CD22 Vector

CD22 Vectors

Specifically designed to overcome resistance in B-cell therapies, backed by research and clinical success, ensuring enhanced outcomes for challenging cases.

Learn More →
BCMA Vector

BCMA Vectors

Advanced vector solution specifically engineered for treating multiple myeloma, demonstrating effectiveness through clinical success.

Learn More →
CD7 Vector

CD7 Vectors

Targeting T-cell malignancies with high specificity and potency, CD7 vectors represent a breakthrough in treating aggressive leukemias and lymphomas.

Learn More →
Dual-Specific CAR T

Boom Platform (Dual-Specific)

Innovative dual-specific CAR T cell therapy platform designed to enhance targeting precision and reduce antigen escape in solid and hematological tumors.

Learn More →
Logic-Gated CAR T

YK-Boost (Logic-Gated)

Logic-gated CAR T cell therapy platform enabling smarter immune responses with enhanced safety profiles and reduced off-target effects.

Learn More →

Bicephali (Multi-Targeting)

Compound CAR T-cell therapy platform capable of targeting multiple antigens simultaneously, improving tumor eradication and reducing relapse.

Learn More →

NKElixir (NK Expression)

Next-generation platform enhancing natural killer (NK) cell expression in CAR therapies, boosting innate immune response and anti-tumor activity.

Learn More →

Empowering Hospitals with In-House CAR T Labs

Beijing Biotech, through VectorGene, is a leading CAR T cell manufacturing and vector supply company in China. We provide turnkey solutions for hospitals to establish in-house CAR T labs — reducing costs, eliminating delays, and ensuring faster, safer, and more effective cancer treatment through localized manufacturing and expert training.

Our mission is to democratize access to cutting-edge CAR T-cell therapies by enabling healthcare institutions across Asia and beyond to produce high-quality, clinically validated treatments locally.

Connect Now
Lab Equipment Research Lab Scientist Team

Advanced Technology Platforms

Our proprietary platforms are revolutionizing CAR T-cell therapy with enhanced targeting, safety, and efficacy.

Boom

Dual-specific CAR T for enhanced tumor targeting and reduced antigen escape.

YK-Boost

Logic-gated CAR T cells for smarter, safer immune responses.

Bicephali

Multi-targeting compound CAR T for improved tumor eradication.

NKElixir

NK-enhanced CAR therapies for stronger innate immune activation.

Research & Clinical Advancement

We have developed over 70 CAR T-cell therapy pipelines. More than 20 have advanced to investigator-initiated clinical trials (IIT) in China. Our collaborative research has been showcased at prestigious conferences including the European Hematology Association and the American Society of Hematology, with over 50 clinical-trial-related papers published in top-tier journals.

70+
CAR T Therapy Pipelines
20+
In Clinical Trials (IIT)
50+
Clinical Trial Publications
Check Our Publications

Get in Touch

Are you ready to revolutionize cancer treatment at your hospital? Let’s collaborate to bring the future of CAR T-cell therapy to your institution.

Contact Information

Phone: +86 182 1759 2149

WhatsApp: +86 182 1759 2149

Email: vectorgenebiotech@gmail.com

Address: 12th Floor, Gobroad Healthcare, Leeza Soho, Beijing - 100070, China

Visit Official Website
China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact support@fobcompany.info

如果您是其他域名合作 也请联系support@fobcompany.info